Early DKD shows activated NRF2 as a compensatory antioxidant response, demonstrated by elevated NRF2 levels and unchanged KEAP1 levels in diabetic patients with CKD stages 0–3b [8]. This evidence concerns the gene KEAP1 and chronic kidney disease.